Literature DB >> 3624908

Self-infusion of intravenous immunoglobulin by immunodeficient patients at home.

H D Ochs, M L Lee, S H Fischer, E S Delson, B S Chang, R J Wedgwood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3624908     DOI： 10.1093/infdis/156.4.652

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  11 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

3.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions.

Authors:  A Gardulf; H Björvell; R Gustafson; L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

5.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

6.  Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home.

Authors:  V M Brennan; S Cochrane; C Fletcher; D Hendy; P Powell
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 7.  Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.

Authors:  S A Schwartz
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 8.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study.

Authors:  Eric Hachulla; Gwendal Le Masson; Guilhem Solé; Mohamed Hamidou; Claude Desnuelle; Jean-Philippe Azulay; Gérard Besson; Laure Swiader; Sébastien Abad; Jean-Christophe Antoine; Françoise Bouhour; Alain Créange; Marike Grenouillet; Laurent Magy; Sébastien Marcel; Jean-Michel Paquet; François Rouhart; François Ziegler; Stéphane Mathis; Marc Gauthier-Darnis; Sophie Puget
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

10.  Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.

Authors:  Gwendal Le Masson; Guilhem Solé; Claude Desnuelle; Emilien Delmont; Marc Gauthier-Darnis; Sophie Puget; Isabelle Durand-Zaleski
Journal:  Brain Behav       Date:  2018-01-26       Impact factor: 2.708
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.